Abstract
Herpesgroup viruses remain cause of morbidity among renal allograft recipients. Over the past several years the development of antiviral drugs such as adenine arabinoside and acyclovir have resulted in major improvements in management of herpes simplex (HSV) and varicella zoster virus (VZV) infections (1). Cytomegalovirus (CMV) and Epstein-Barr virus (EBV), however, continue to contribute to the morbidity of renal transplantation (2–6). CMV infection has several effects on the host. Between 30 and 40% of all renal allograft recipients develop clinically apparent CMV syndromes and 2–3% will have fatal infections. CMV infection following transplantation may be either primary or due to reactivation of latent virus. Primary infection occurs in 60–70% of CMV seronegative renal allograft recipients who receive grafts from CMV seropositive donors. Reactivation of CMV occurs in approximately 60% of CMV seropositive recipients. Because most adult allograft recipients in the United States are CMV seropositive, primary CMV infections are less common than reactivation infections, but may be associated with more morbidity when they are observed.
This work was supported by grants CA12464 and AI17057 and contract NO1CP43222 from the National Institute of Health.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Hirsch MS, Schooley RT. Treatment of herpesvirus infections. N Engl J Med 1983; 309: 963.
Glenn J. Cytomegalovirus infections following renal transplantation. Rev Infect Dis 1981; 3: 1151–78.
Marker SC, Howard RJ, Simmons RL, et al. Cytomegalovirus infection: A quantitative prospective study of three hundred twenty consecutive renal transplants. Surgery 1981; 89: 660–71.
Harwood AR, Osoba D, Hofstader SL, et al. Kaposi’s sarcoma in recipients of renal transplants. Am J Med 1979; 67: 759–65.
Richardson WP, Colvin RB, Cheeseman SH, et al. Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med 1980; 305: 57–63.
Hanto DW, Frizzera G, Gejl-Peczalaska J, et al. The Epstein-Barr virus in the pathogenesis of post transplant lymphoma. Transplant Proc 1981; 13: 756–60.
Ho M. Cytomegalovirus: Biology and infection. New York, Plenum, 1982.
Carney WP, Hirsch MS. Mechanisms of immunosuppression in cytomegalovirus mononucleosis. II. Virus-monocyte interactions. J Infect Dis 1981; 144: 47–54.
Carney WP, Rubin RH, Hoffman RA, Hansen WP, Healey K, Hirsch MS. Analysis of T lymphocyte subsets in cytomegalovirus mononucleosis. J Immunol 1981; 126: 2114–6.
Schooley RT, Hirsch MS, Colvin RB, et al. Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N Engl J Med 1983; 308: 307–13.
Colvin RB, Cosimi AB, Burton RC, et al. Circulating T-cell subsets in human renal allograft recipients: The OKT4+/OKT8+ cell ratio correlates with reversibility of graft injury. Presented at the 9th International Congress of the Transplantation Society, Brighton, United Kingdom, 1982 August 23–27.
Cheesemen SH, Henle W, Rubin R, et al. Epstein-Barr virus infection in renal transplant recipients: Effects of antithymocyte globuline and interferon. Ann Intern Med 1980; 93: 39–42.
Cantell K, Hirvonen S, Kauppinen H-L, Myllyla G. Production of interferon in human leukocytes from normal donors with the use of Sendai virus. Methods Enzymol 1981; 78: 29–38.
Cantell K, Hirvonen S, Koistinen V. Partial purification of human leukocyte interferon on a large scale. Methods Enzymol 1981; 78: 499–505.
Cheeseman SH, Rubin RH, Stewart JA, et al. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med 1979; 30: 1345–9.
Reedman BM, Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer 1973; 11: 499–520.
Henle G, Henle W. Immunofluorescence in cells derived from Burkitt’s lymphoma. J Bacteriol 1966; 91: 1248–56.
Henle G, Henle W, Klein G. Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells. Int J Cancer 1971; 8: 272–82.
Rubin RH, Cosimi AB, Tolkoff-Rubin NE, Russell PS, Hirsch MS. Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation 1977; 24: 458–64.
Hirsch MS, Schooley RT, Cosimi AB, et al. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients. N Engl J Med 1983; 308: 1489–93.
Horning SJ, Levine JF, Miller RA, Rosenberg SA, Merigan TC. Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. JAMA 1982; 247: 1718–22.
Scott GM, Phillpotts RJ, Wallace J, Gauci CL, Greiner J, Tyrrell DAJ. Prevention of rhinovirus colds by human interferon alpha-2 from Escherichiacoli. Lancet 1982;ii:186–8.
Starr SE, Glazer JP, Friedman HM, Farquhar JD, Plotkin SA. Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine. J Infect Dis 1981; 143: 585–9.
Zaia JA, Levin MJ, Leszczynski J, Wright GG, Grady GF. Cytomegalovirus immune globulin: production from selected normal donor blood. Transplantation 1979; 27: 66–7.
Andrus CH, Betts RF, May AG, Freeman RB. Cytomegalovirus infection blocks the beneficial effect of pretransplant blood transfusion on renal allograft survival. Transplantation 1979; 28: 451–6.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Schooley, R.T., Hirsch, M.S., Rubin, R.H., Cantell, K. (1984). The Role of Interferons in Viral Infections in Immune Compromised Patients. In: Smit Sibinga, C.T., Das, P.C., Opelz, G. (eds) Transplantation and Blood Transfusion. Developments in Hematology and Immunology, vol 10. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3840-6_11
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3840-6_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3842-0
Online ISBN: 978-1-4613-3840-6
eBook Packages: Springer Book Archive